Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-296-3p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
MK2
Cancer name
Nasopharyngeal Carcinoma
Cancer site
Nasopharynx
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
110
Male patients
75
Female patients
35
Age range and number
52(<50)+58(>=50)
PMID
Description
MiR-296-3p may thus serve as a therapeutic target to reverse chemotherapy resistance of NPC.
Tissue resource
primary fresh nasopharyngeal carcinoma samples and normal fresh nasopharyngeal samples
EBV-negative cell lines HONE1
nasopharyngeal carcinoma cell lines SUNE1
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Nanfang Medical Hospital of Guangzhou City
Cancer Center of Sun Yat-sen University
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.